DeutschNewstral
Article
bizjournals.com on 2020-04-27 12:04
Cambridge biotech launches with $50M to target 'junk DNA'
Related news
- Cambridge biotech Visterra yanks plan for $50M IPO, citing bad market conditionsbizjournals.com
- Cambridge biotech delivers coronavirus vaccinebizjournals.com
- PureTech’s microbiome biotech gets $50M VC investmentbizjournals.com
- Cambridge fintech raises $50M, makes two acquisitionsbizjournals.com
- Biotech startup expands from Cambridge to Watertownbizjournals.com
- Cambridge biotech to return its PPP loanbizjournals.com
- Cambridge biotech relocates to West Coastbizjournals.com
- Cambridge biotech plans manufacturing hub in Marylandbizjournals.com
- Cambridge biotech Werewolf gets $72M funding roundbizjournals.com
- Presbyterian Homes to invest $50M in Cambridge facilitybizjournals.com
- With eye on blockchain, Cambridge VC firm raises $50M fundbizjournals.com
- Picture this: Fujifilm invests in Cambridge biotech startupbizjournals.com
- Biotech wunderkind Vivek Ramaswamy opens first Cambridge outpostbizjournals.com
- Eli Lilly will pay $960M for migraine-focused Cambridge biotechbizjournals.com
- After Biogen deal, Florida biotech opening Cambridge officebizjournals.com
- West Cambridge biotech firm with connections to Genzyme raises $21Mbizjournals.com
- Cambridge biotech tripling size of Kendall Square HQbizjournals.com
- A requirement at this Cambridge biotech: Must love dogsbizjournals.com
- Cambridge biotech startup grabs $65M to tackle liver diseasebizjournals.com
Cambridge cluster companies dominate the Biotech and Money Annual Awardscambridgeindependent.co.uk